Illumina v. Molecular Loop: Genomics Patent Case Transferred to Delaware in Just 54 Days
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Illumina Inc. v. Molecular Loop Biosciences Inc. |
| Numéro de dossier | 1:24-cv-11501 (D. Mass.) & D. Del. successor docket |
| Tribunal | U.S. District Court for the District of Massachusetts (Transferred to D. Del.) |
| Durée | June 9, 2024 – August 2, 2024 54 days |
| Résultat | Procedural: Venue Transferred |
| Brevets en cause | |
| Produits incriminés | TruSight Oncology 500 ctDNA v2, VeriSeq NIPT Solution v2 assay |
Aperçu du dossier
Les parties
⚖️ Demandeurs
Global market leader in DNA sequencing and array-based technologies with an extensive IP portfolio in genomics and non-invasive prenatal testing (NIPT).
🛡️ Défendeur
Genomics company offering sequencing-based assay solutions, active in liquid biopsy and oncology sequencing markets.
Les brevets en cause
This case involved five U.S. patents asserted by Illumina, Inc. and Verinata Health, Inc., covering critical technologies in next-generation sequencing (NGS), non-invasive prenatal testing (NIPT) methodology, and circulating tumor DNA (ctDNA) detection. These patents are registered with the U.S. Patent and Trademark Office (USPTO).
- • US11768200B2 (App. No. US17/339527) — Sequencing chemistry
- • US11840730B1 (App. No. US16/952764) — Sequencing chemistry
- • US11041851B2 (App. No. US14/854629) — NIPT methodology
- • US9163281B2 (App. No. US13/081660) — ctDNA detection
- • US11041852B2 (App. No. US17/149504) — NIPT methodology
Developing a new genomics assay?
Check if your NGS or liquid biopsy product might infringe these or related patents before launch.
Le verdict et l'analyse juridique
Résultat
The Massachusetts District Court did not issue a merits ruling. The case was terminated in Massachusetts upon transfer to the District of Delaware pursuant to the parties’ Joint Motion to Transfer Venue. No damages were awarded, no injunctive relief was granted or denied, and no findings on validity or infringement were made at this stage.
The case remains active — now repositioned in Delaware for substantive adjudication.
Principales questions juridiques
The sole dispositive action in Massachusetts was procedural: a consent-based venue transfer. The joint nature of the motion is strategically significant, indicating that both parties reached an agreement that Delaware was the more appropriate forum, avoiding a contested transfer motion that could have delayed proceedings and created early adversarial friction. Under 28 U.S.C. § 1404(a), courts may transfer cases for convenience of the parties and witnesses, or in the interest of justice.
Delaware’s District Court handles a disproportionate share of U.S. patent litigation due to its extensive IP expertise, well-developed local patent rules, and highly regarded docket management for complex multi-patent cases.
Freedom to Operate (FTO) Analysis in Genomics
This case highlights critical IP risks in NGS and liquid biopsy. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- Voir tous les brevets liés à ce domaine technologique
- See which companies are most active in genomics patents
- Understand claim construction patterns specific to NGS
🔍 Vérifier les risques liés à mon produit
Effectuez une analyse FTO complète pour votre propre technologie ou produit.
- Input your product description (e.g., NGS assay, NIPT solution)
- L'IA identifie les brevets susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
NGS and Liquid Biopsy Platforms
5 brevets revendiqués
In genomics sequencing technology
Contournements stratégiques
Possible with FTO planning
✅ Points clés à retenir
Joint venue transfer motions are efficient tools for repositioning complex cases without adversarial delay.
Rechercher la jurisprudence connexe →Portfolio assertions (5+ patents) are increasingly standard in genomics patent enforcement, maximizing leverage.
Découvrez les outils d'analyse de portefeuille →Delaware remains the preferred forum for multi-patent biotech disputes; counsel should anticipate this in initial venue analysis.
Understand Delaware’s patent rules →Foire aux questions
Five U.S. patents were asserted: US11768200B2, US11840730B1, US11041851B2, US9163281B2, and US11041852B2 — covering NGS, NIPT, and ctDNA detection technologies.
Both parties jointly moved for transfer under 28 U.S.C. § 1404(a). The court granted the motion on August 2, 2024, citing the parties’ agreement that Delaware was the more appropriate forum.
It reinforces Delaware’s dominance as the preferred venue for complex biotech IP disputes and signals active enforcement of Illumina’s sequencing patent portfolio against commercial competitors in liquid biopsy and NIPT markets.
Ready to Strengthen Your Genomics IP Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision in life sciences.
Références
- PACER: U.S. District Court for the District of Massachusetts — Case No. 1:24-cv-11501
- Office américain des brevets et des marques — Centre des brevets
- Cornell Legal Information Institute — 28 U.S.C. § 1404(a)
- PatSnap — IP Intelligence Solutions for Life Sciences
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.